Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Angiotensin-(1-7) vs Cartalax
An educational, source-based comparison of Angiotensin-(1-7) and Cartalax — how each peptide works, what it's researched for, and what to know before going deeper.
Counter-regulatory peptide of the renin-angiotensin system.
A heptapeptide of the renin-angiotensin system that acts on Mas receptors. Research demonstrates counter-regulatory effects to angiotensin II, promoting vasodilation, anti-inflammatory signaling, and anti-fibrotic effects in cardiovascular and renal tissues.
- Pulmonary hypertension and fibrosis
- Heart failure with preserved ejection fraction
- Acute lung injury and ARDS
- Diabetic nephropathy
- • Investigational; not FDA-approved.
- • Interaction with ACE inhibitors and ARBs requires careful study design.
Tripeptide bioregulator researched for cartilage and joint support.
A synthetic tripeptide (Ala-Glu-Asp) in the Khavinson short-peptide family. Research suggests gene-expression modulation in chondrocytes and fibroblasts, supporting extracellular matrix synthesis and reducing cartilage degradation markers.
- Osteoarthritis and cartilage repair
- Joint mobility in aging
- Tendon and ligament integrity
- • Preclinical and Russian clinical data only.
- • Not FDA-approved.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Angiotensin-(1-7) | Angiotensin-(1-7) as a therapeutic in lung disease | American Journal of Respiratory and Critical Care Medicine | 2020 | Demonstrated protective effects in acute lung injury and pulmonary fibrosis models. |
| Angiotensin-(1-7) | Mas receptor activation in cardiovascular protection | Circulation Research | 2018 | Reviewed anti-inflammatory and anti-fibrotic mechanisms in cardiac tissue. |
| Cartalax | Cartalax and chondrocyte gene expression | Bulletin of Experimental Biology and Medicine | 2015 | Modulated collagen type II and aggrecan expression in cultured chondrocytes. |
Side-effect & safety grid
- Investigational; not FDA-approved.
- Interaction with ACE inhibitors and ARBs requires careful study design.
- Preclinical and Russian clinical data only.
- Not FDA-approved.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Angiotensin-(1-7) vs Cartalax — Key differences
- Class: Angiotensin-(1-7) is classified as Cardiovascular · Anti-inflammatory, while Cartalax is Musculoskeletal · Bioregulator.
- Primary research focus: Angiotensin-(1-7) — pulmonary hypertension and fibrosis; Cartalax — osteoarthritis and cartilage repair.
- Tag: Cardiovascular · Anti-inflammatory vs Joint · Bioregulator.